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Background: COX-2 inhibitors have an antitumor potential and have been verified by many researchers. Treatment
of cancer cells with external stressors such as irradiation can stimulate the over-expression of COX-2 and possibly
confer radiation resistance. In this study, we tested if topical diclofenac, which inhibits both COX-1 and COX-2,
administration rendered prostate tumor cells sensitize to the effects of radiation.
Methods: LNCaP-COX-2 and LNCaP-Neo cells were treated with 0 to 1000 μM diclofenac. Next, a clonogenic assay
was performed in which cells were subjected to irradiation (0 to 4 Gy) with or without diclofenac. COX-2 expression
and other relevant molecules were measured by real-time PCR and immunohistochemistry after irradiation and
diclofenac treatment. In addition, we assessed the tumor volumes of xenograft LNCaP-COX-2 cells treated with
topical diclofenac with or without radiation therapy (RT).
Results: LNCaP-COX-2 and LNCaP-Neo cell lines experienced cytotoxic effects of diclofenac in a dose related
manner. Clonogenic assays demonstrated that LNCaP-COX-2 cells were significantly more resistant to RT than
LNCaP-Neo cells. Furthermore, the addition of diclofenac sensitized LNCaP-COX-2 not but LNCaP-Neo cells to the
cytocidal effects of radiation. In LNCaP-COX-2 cells, diclofenac enhanced radiation-induced apoptosis compared
with RT alone. This phenomenon might be attributed to enhancement of RT-induced TRAIL expression as
demonstrated by real-time PCR analysis. Lastly, tumor volumes of LNCaP-COX-2 cells xenograft treated with
diclofenac or RT alone was >4-fold higher than in mice treated with combined diclofenac and radiation (p<0.05).
Conclusions: These in vitro and in vivo findings suggest that conventional COX inhibitor, diclofenac enhances the
effect of RT on prostate cancer cells that express COX-2. Thus, diclofenac may have potential as radiosensitizer for
treatment of prostate cancer.
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Figure 1 Effects of diclofenac on LNCaP-COX-2 cells and
LNCaP-Neo. Cells were seeded in 96-well plate, and treated with
indicated concentration of diclofenac for 72 hours. Cytotoxicity was
determined by WST-8 assay. Diclofenac reduced cell viability in both
LNCaP-COX-2 cells and LNCaP-Neo cells in a dose-dependent
manner. LNCaP-COX-2 cells significantly exhibited higher sensitivity
to diclofenac than LNCaP-Neo cells. Cell viability at 10 μM in LNCaP-
COX-2 and LNCaP-Neo was 74.0% and 95.7% (p = 0.0094), 51.6%
and 73.8% at 50 μM (p < 0.0001), 31.7% and 45.7% at 100 μM
(p < 0.0001). Absorbance values were normalized to values for
vehicle only treated cells (control), and the results are expressed
as the mean ± SD of sextuplet samples.
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Cyclooxygenase (COX; prostaglandin G/H synthase, EC
1.14.99.1) is a key enzyme that catalyzes the conversion
of arachidonic acid to prostaglandins (PGs) and other
prostanoids.
Two isoforms of COX have been identified, COX-1 and
COX-2 [1]. Recently, a splicing variant of COX-1 was
identified. Alternative splicing generates four different
mRNA variants derived from the COX-1 gene - COX-1,
COX-3, and two partial COX-1s (PCOX-1 proteins).
COX-3 and one of the PCOX-1 proteins (PCOX-1a) are
made from the COX-1 gene but retain intron 1 in their
mRNAs [2,3]. COX-1, constitutively expressed in almost
tissues, is required for homeostatic functions, whereas
COX-2, an inducible enzyme, is up-regulated by growth
factors, tumor promoters, oncogenes and carcinogens
[1,4-6].
Of the two isoforms, COX-2 is consistently up-
regulated in a number of cancers, including esophagus
[7], stomach [8], colon [9], lung [10], pancreas [11], head
and neck [12], and prostate [13]. In addition, COX-2 ex-
pression is associated with aggressive tumor behavior,
worse prognosis and the development of metastatic
disease [14].
On immunohistochemical (IHC) staining of prostate,
the expression of COX-2 protein in prostate cancer
(PCa) was significantly higher than that in benign pros-
tatic hyperplasia (BPH) and normal prostate, while the
expression of COX-1 protein was not significantly differ-
ent between BPH and PCa. Furthermore, the intensity of
COX-2 expression increased with increasing tumor
grade [13,15,16].
Clinical, and animal studies indicate that the use of as-
pirin and other non-steroidal anti-inflammatory drugs
(NSAIDs) can significantly reduce the risk of colorectal,
breast, prostate, lung and esophageal cancer [4,17-19].
As for prostate cancer, recent epidemiological studies
indicated that use of aspirin and other NSAIDs reduces
the risk of prostate cancer by 20-30% [20].
A number of studies suggest that COX-2 expression is
not only an early event in the carcinogenesis, but is
required throughout the entire evolutionary process of
cancer development and progression [18]. Furthermore,
it has been proposed that COX-2 may regulate the ex-
pression of genes that contribute to tumor cell survival,
aggressiveness, and angiogenesis. A number of previous
studies have shown that PGs can act as potent radiore-
sistant factors of some cancers, and their inhibition
resulted in radiosensitization [21-24]. Therefore, COX-2,
which induced PGs, is considered to be potential targets
for anticancer therapy. Although COX is the only mo-
lecular target known of most NSAIDs, both COX-
dependent and COX-independent mechanism in the
apoptotic action of NSAIDs have been reported [25-28].Diclofenac is a selective COX-1 and COX-2 inhibitor.
The reason why we used this drug in this study was
that diclofenac was a widely used non-steroidal anti-
inflammatory drug and topical diclofenac was available.
In the present study, we investigated the role of COX-
2 expression in radioresistance and the effect of diclofe-
nac on the cell viability and radiosensitivity of prostate
cancer cells in vitro experiments. Furthermore, we inves-
tigated the efficacy of treatment with topical diclofenac
using diclofenac gel in vivo experiment.Results
Effect of diclofenac on cell viability of prostate cancer
cells
To evaluate the antitumor potential of diclofenac on cell
viability and whether COX-2 expression contributes to
cell proliferation, LNCaP-COX-2 cells and LNCaP-Neo
were treated with various concentrations of diclofenac
for 72 hours.
Diclofenac reduced cell viability in both LNCaP-COX-
2 cells and LNCaP-Neo in a dose-dependent manner
(Figure 1). However, LNCaP-COX-2 cells significantly
showed higher sensitivity to diclofenac than LNCaP-
Neo. Cell viability at 50 μM in LNCaP-COX-2 and
LNCaP-Neo was 51.6% and 73.8%, respectively (p <
0.0001). The diclofenac 50% inhibitory concentration
(IC50) was calculated in LNCaP-COX-2 and LNCaP-
Neo and found to be 42.2 μM and 91.6 μM, respectively.
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be attributed to the level of COX-2 expression.
Effect of diclofenac on radiosensitivity of prostate cancer
cells
To determine the effect of diclofenac on radiosensitivity
of prostate cancer cells, we next examined a clonogenic
assay. LNCaP-COX-2 and LNCaP-Neo cells were treated
with 10.9 μM and 46.7 μM (respective IC25 of cell lines)
of diclofenac for 48 hours before irradiation (0, 2 or
4 Gy). The survival fraction of both LNCaP-COX-2 cells
and LNCaP-Neo cells was decreased in a radiation dose-
dependent manner (Figure 2A, 2B). The survival frac-
tions at 2 Gy dose without diclofenac were 78.6% and
38.2% (p = 0.0466) for LNCaP-COX-2 and LNCaP-Neo,
respectively. LNCaP-COX-2 cells were proved to beFigure 2 Clonogenic assay for LNCaP-COX-2 and LNCaP-Neo treated w
treated with irradiation (0, 2 or 4 Gy) with or without diclofenac (IC25). Cell
for 48 hours, irradiated, and allowed to form colonies. (A) Survival fractions
survival fractions for untreated cells. LNCaP-COX-2 cells was more radioresis
diclofenac enhanced the effect of RT with significant differences between
(p = 0.0466). (B) Clonogenic assay of LNCaP-COX-2 cells and LNCaP-N
Photographs of 6-well plates in a representative experiment are showmore radioresistant than LNCaP-Neo cells. Furthermore,
diclofenac significantly sensitized the LNCaP-COX-2
cells to RT. However, this effect was not observed in
LNCaP-Neo cells. In LNCaP-COX-2 cells, the survival
fractions at 2 Gy dose were 78.6% and 35.5% for radi-
ation alone and radiation with diclofenac, respectively
(p = 0.0225), while the survival fractions were 38.2% and
30.0%, respectively in LNCaP-Neo (p = 0.4232). This
data suggested that COX-2 overexpression protected
LNCaP-COX-2 cells from the effect of irradiation and
that inhibition of COX-2 sensitized to RT.
Diclofenac suppressed RT-induced COX-2 up-regulation
and enhanced the induction of TRAIL
Next, we set out to assess the molecular profile of trea-
ted cells using real-time PCR analysis. We focused onith irradiation. Clonogenic assay for LNCaP-COX-2 and LNCaP-Neo
s were seeded in 6-well plate, and treated with or without diclofenac
for radiation and diclofenac were normalized by dividing by the
tant than LNCaP-Neo cells (p = 0.0225). In LNCaP-COX-2 cells,
RT alone and RT with diclofenac, when cells were exposed to 2 Gy
eo cells treated with RT (0, 2 or 4 Gy) and diclofenac (0 or IC25).
n.
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release of TRAIL in response to RT since TRAIL is a
most common RT-inducible cytokine [29-31]. In
LNCaP-COX-2 cells, RT induced COX-2 up-regula-
tion but diclofenac inhibited RT-induced COX-2
up-regulation (Figure 3A). Furthermore, RT induced
TRAIL, and combination with diclofenac enhanced
the induction of TRAIL (Figure 3B). Thus, diclofenac
made LNCaP-COX-2 cells more sensitive to apop-
tosis through induction of TRAIL.
Combination of diclofenac and radiation induced
apoptosis in LNCaP-COX-2 cells
According to the results of real-time PCR analysis,
TRAIL mRNA expression was found to induce by diclo-
fenac. Consequently, to determine whether the combin-
ation of diclofenac and radiation was related with
apoptosis, cells were treated with diclofenac (IC50) for
3 hours, thereafter irradiated with 2 Gy. After incubationFigure 3 Real-time PCR analysis for COX-2 (A) and TRAIL (B). RT
induced COX-2 up-regulation, and diclofenac inhibited RT-
induced COX-2 up-regulation. Combination of radiation and
diclofenac significantly enhanced the effect of RT on induction
of TRAIL (p < 0.05).for 3 hours, the cells were harvested to examine apop-
tosis using Cell Death Detection ELISAPlus kit according
manufacturer’s instructions. Apoptosis was not signifi-
cantly induced in cells treated with either diclofenac
alone or radiation alone compared with untreated cells.
However, combined treatment of diclofenac and irradi-
ation was significantly induced apoptosis much than un-
treated cells (Figure 4). This apoptosis was responsible
for induction of TRAIL that induced by combined
treatment.
Topical treatment with diclofenac reduced tumor growth
and enhanced the effect of RT in vivo xenograft mouse
model, and suppressed both COX-2 and Ki-67 expression
To confirm radiosensitizing effect of diclofenac in vivo,
we conducted animal experiments using xenograft
mouse model of LNCaP-COX-2. The xenograft mice
bearing LNCaP-COX-2 tumor were treated with topical
administration of diclofenac gel onto mice skin with cot-
ton swab once a day with or without irradiation (3 Gy)
to the subcutaneous tumor on day 3. Treatment with
diclofenac reduced tumor growth to 37.0% compared to
control, whereas treatment with 3 Gy radiation reduced
tumor growth to 57.0% compared to control. The mean
relative tumor volumes in control and combined treat-
ment (RT and diclofenac) groups on day 36 were 35.74
fold-change and 5.96, respectively (p < 0.05). In addition,
combination therapy resulted in enhanced antitumor po-
tential compared with diclofenac alone or radiation
alone (Figure 5A). No weight loss was observed in any
of the experimental groups (data not shown).
To investigate the cell proliferation status and level of
COX-2 expression in the treated and control tumors,
the expression of Ki-67 and COX-2 were analyzed with
IHC staining. The expression of COX-2 decreased inFigure 4 Combined treatment with radiation and diclofenac
increased an induction of apoptosis compared with either
alone. Cells were incubated for 24 hours, and treated with
diclofenac (IC25) for 48 hours, then exposed to radiation (0, 2 Gy).
Apoptosis induction was quantified using Cell Death Detection
ELISA kit.
Figure 5 Diclofenac induced the tumor growth delay and enhanced the effect of RT in xenograft mouse model of LNCaP-COX-2. The
xenograft mice bearing LNCaP-COX-2 tumor were treated with topical administration of diclofenac gel onto mice skin with cotton swab once a
day (day 1–36). The tumors in RT alone group and combination group were exposed to IR with a single dose of 3 Gy on day 3. Tumor volume
was measured with calipers and calculated as 0.52LW2. (A) Tumor volume was significantly reduced in combination group. (B)
Immunohistochemical staining for COX-2 and Ki-67 was conducted. The expression of COX-2 decreased in diclofenac group and combination
group compared with control group, while the expression of COX-2 increased in RT group. The expression of Ki-67 significantly decreased in
diclofenac group and combination group. Original magnification, x200.
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control group, while the expression of COX-2 increased
in RT group. The expression of Ki-67, proliferative index
(PI), significantly decreased in diclofenac group (PI:
0.21) and combination group (PI: 0.31) compared with
control group (PI: 0.61) (Figure 5B).
Discussion
PCa is the most common solid tumor in US males and
the second leading cause of cancer related deaths [32]. A
common treatment option for localized PCa is RT,
which may possess similar survival rates at 5, 10, and
15-years to radical prostatectomy. Though radiation
dose increase has associated with higher cancer control
rates, high dose radiation can cause important side
effects, such as urinary dysfunction, impotence, and rec-
tal symptoms. Several reports have demonstrated that
the addition of androgen deprivation to RT may
improved the results of patients with intermediate- and
high-risk PCa. However in high-risk patients treated
with RT, 5-year recurrence free survival is approxi-
mately 50%.Thus, new molecular targets for the enhancement of
RT and regression of RT adverse event are needed for
some patients with localized prostate cancer.
NSAIDs have been demonstrated to potentiate radio-
sensitivity of cancer cells, and recent studies reported
the radiosensitizing effect of selective COX-2 inhibitors
on tumor cells [23-25,33].
The cells overexpressing COX-2 tend to be resistant to
apoptosis, and COX-2 inhibitors have been shown to in-
duce apoptosis in these types of cells. Therefore, we
hypothesized that the COX inhibitor, diclofenac could
enhance the effect of radiation on prostate cancer cells
that constitutively express COX-2.
Although many of recent studies reported about the
relation between COX inhibitor and radiosensitizing ef-
fect, conducted chiefly in vitro experiments study. We
further attempted to show the potentiation of RT in vivo
experiments.
This study is the first evidence that treatment with
diclofenac increased the radiosensitivity of prostate can-
cer cells by suppression of COX-2 up-regulation and in-
duction of TRAIL in vitro, and that topical treatment
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in vivo.
The underlying mechanism responsible for the antitu-
mor effect of COX inhibitor has not been clearly eluci-
dated, although several possibilities have been proposed,
i.e. modulation of angiogenesis, regulation of cell cycle,
and reverse of PGs-induced immunosuppression [9].
PGs, which were produced by COX-2, have been pro-
posed to promote the proliferation and metastasis of
cancer cells and secondarily encourage the growth of
cancer cells by immunosuppression. Furthermore, PGE1
and PGE2 are known to induce angiogenesis [9,18].
Milas and his colleagues demonstrated that the NSAID
indomethacin prolongs tumor growth delay and
increases the tumor cure rate after radiotherapy [22,24].
It has been proposed that NSAIDs increased tumor radi-
ation response by lowering the level of PGs in the tumor
[23]. Based on recent findings that PGs and COX-2
are radioprotective factors, it is reasonable to assume
that diclofenac inhibited tumor cell proliferation and
increased tumor radiosensitivity by reducing tumor-
producing PGs [34,35]. Recent experiments using
selective or not selective COX-2 inhibitor, including
celecoxib and NS-398, demonstrated that COX-2
overexpression might be responsible for radioresis-
tance [6,25], and that suppression of COX-2 overex-
pression render cells susceptible to RT.
NSAIDs have been demonstrated to potentiate the
effect of RT on cancer cells in vitro and in vivo,
however, no study has reported on the efficacy of
topical diclofenac gel.
In this study, we investigated the antitumor poten-
tial and the radiosensitizing effect of diclofenac on
prostate cancer cells. In LNCaP-COX-2 cells, diclofe-
nac significantly reduced the cell viability and sensi-
tized to RT. COX-2 overexpression is responsible for
radioresistance in clonogenic assay. LNCaP-COX-2
cells were more susceptible to diclofenac than
LNCaP-neo cells. These findings suggested that
LNCaP-COX-2 might be addictive to COX-2 than
LNCaP-Neo cells, and that COX-2 might be one of
survival factors for LNCaP-COX-2 cells. We first
showed that the combination of RT and topical
treatment with diclofenac gel significantly induced
the tumor growth delay than either treatment alone
in prostate cancer tumor in vivo. The radiosensitiz-
ing effect of diclofenac was not observed in LNCaP-
Neo cells that lacked COX-2 expression.
In real-time PCR analysis, RT induced TRAIL and
combination with diclofenac enhanced the RT-
induced TRAIL.
We first suggested that additional aspects of the COX
inhibitor, diclofenac-induced potentiation of tumor
radioresponse were caused by the induction of TRAIL.TRAIL is an identified member of the TNF ligand
family that can induce a rapid caspase-dependent apop-
tosis with high specificity for malignant cells.
Recent study has been shown that significant release
of TNF-related apoptosis inducing ligand was observed
in response to ionizing radiation(IR) in lung cancer
cells [36], and that IR up-regulates TRAIL-Receptor
surface expression [37]. TNF-α and TRAIL are dir-
ectly involved in apoptosis and are induced by IR
[38]. Irradiation induced release of tumor necrosis
factor-α, or TRAIL [36].
Our findings that RT significantly induced TRAIL in
real-time PCR analysis are consistent with these results.
In addition, combination of RT and diclofenac signifi-
cantly increased the induction of TRAIL compared with
either alone. The enhancement of TRAIL can explained
the observed increase of apoptosis.
Apoptosis is controlled via two major pathways, in-
cluding one that originates at the cell membrane and
another that involves the mitochondria. The membrane
death receptor (DR) pathway involves DRs such as Fas,
TNF-R1, DR-3, DR-4, and DR-5, that are activates by
their respective ligands and engages the intracellular
apoptotic machinery. In addition, caspase pathway is
involved in TRAIL-induced cell death, and IR-induced
TRAIL contributed to cell death via increase of caspase-
8, caspase-9, and caspase-3 activation. COX-2 expression
has shown to significantly attenuate TRAIL-induced cas-
pase-8, caspase-9, and caspase-3 [31]. NSAIDs, sulindac
sulfide, increased both DR-4 and DR-5 mRNA levels.
Modulation of the level of DR-5 regulated the apoptotic
response to TRAIL [31]. RT induced TRAIL in both
LNCaP-COX-2 and LNCaP-Neo cells (data not shown)
in real time PCR analysis. COX-2 overexpression was
shown to attenuate the effect of TRAIL-induced apop-
tosis and reduce Fas-mediated apoptosis [31,39].
Conclusions
This study reveals that COX-2 is a surviving factor asso-
ciated with radiation resistance. Diclofenac sodium sup-
pressed COX-2, induced by irradiation, which rendered
cells resistant to RT. In addition, combination therapy of
RT plus diclofenac enhanced the expression of TRAIL,
and therefore induced apoptosis in prostate cancer cells
compared with RT or diclofenac alone. These findings
suggest that diclofenac may be the effective radio-
sensitizer against human prostate cancer over-
expressed COX-2.
Methods
Chemical compounds and reagents
A selective COX-1 and COX-2 inhibitor, diclofenac so-
dium (diclofenac), was purchased from Sigma-Aldrich
(St Louis, MO, USA). For in vitro studies, diclofenac was
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50 mM and this stock was diluted in media just before
use. For in vivo studies, diclofenac sodium 1% topical
gel was purchased from Novartis Pharma AG (Basel,
Switzerland).
Cell culture and transfection
The human prostate cancer cell line LNCaP was purchased
from American Type Culture Collection (Manassas, VA,
USA) and was maintained in RPMI 1640 supplemented
with 10% fetal bovine serum, penicillin-streptomycin (100
units/ml and 10 μg/ml) in a standard incubator at 37°C
with 5% CO2.
LNCaP-COX-2 cells, stably transfected to overexpress
COX-2, and LNCaP-Neo cells as the control were kindly
provided by Dr. Astushi Mizokami (Kanazawa, Japan).
Irradiation procedures
To determine sensitivity to irradiation, plated prostate
cells were exposed to radiation dose using a MBR-1520R
X-ray unit (Hitachi Medical Co., Tokyo, Japan). The ir-
radiation for in vivo experiments was described later.
In vitro cell viability assay
Cells were seeded in a 96-well plate at a density of
2,000 cells per well in growth media and incubated
for 24 hours. They were treated with various con-
centrations of diclofenac sodium ranging from 0–
1000 μM. After incubating the plates for 48 hours,
cell viability was determined using a Cell Counting
Kit-8 (Dojindo Labor-atories, Kumamoto, Japan)
according to the manufacturer’s instructions. The
viability index was expressed by relative value to the
untreated cells. Each assay was performed in sextu-
plet. Dose response curves were generated. The data
are expressed as means ± standard deviations (SD).
Clonogenic assay
Cells were seeded in a 6-well plate at a density of 10 × 104
cells per well in growth medium, and incubated for
24 hours. Then the cells were treated with 25% inhibitory
concentration (IC25) of diclofenac sodium for 48 hours
and the plates were exposed to 0–4 Gy radiation. Immedi-
ately after irradiation, the cells were trypsinized, serial
diluted and seeded into 6-well plates. The plates were
incubated for 14 days to allow colony formation. The
colonies were stained with 0.25% crystal violet in ethanol
and counted by eye with a cutoff of 50 viable cells. The
survival fraction was calculated relative to non-irradiated
cells. Data were shown as means ± SD.
Real-time PCR analysis
Total RNA was extracted from cells using a QIAamp
RNA Blood Mini kit according the manufacturer’sinstructions (Qiagen, Valencia, CA, USA). RNA concen-
trations were determined by UV spectrophotometer, and
2 μg of total RNA was reverse transcribed into cDNA
using the High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Foster City, CA, USA). Real-
time PCR was performed on a StepOne Plus™ Real-time
PCR system (Applied Biosystems) with Fast SYBR Green
Master Mix (Applied Biosystems). The PCR primer used
in this study were: ACTB forward 50-CTGGAACGGT
GAAGCTGACA-30 and reverse 50-CGGCCACATTGT
GAACTTTG-30, COX-2 forward 50-TGCATTCTTTGC
CCAGCACT-30 and reverse 50-AAAGGCGCAGTTTAC
GCTGT-30,TRAIL forward 50-GAAGCAACACATTGT
CTTCTCCAA-30 and reverse 50-TTGCTCAGGAAT
GAATGCCC-30.
The results were analyzed with the StepOne Software
version 2.0 (Applied Biosystems), using β-actin gene ex-
pression as an internal control.
Apoptosis measurement with cell death detection
ELISAPlus assay
The Cell Death Detection ELISAPlus kit (Roche Molecu-
lar Biochemicals, Mannheim, Germany) was used to
measure DNA fragmentation as a marker for apoptosis
according to the manufacturer’s instructions.
Briefly, cells were seeded in 96-well plate at a density
of 2,000 cells per well, and incubated for 24 hours. Con-
sequently, the cells were treated with diclofenac sodium
concentration (IC25) for 48 hours and the plates were
exposed to 0–2 Gy radiation.
Cytoplasmic fractions of control and treated cells were
transferred into streptavidin-coated 96-well plates and incu-
bated with biotinylated mouse anti-histone antibody and
peroxidase-conjugated mouse anti-DNA antibody at room
temperature for 2 hours. The rate of apoptosis was deter-
mined by measurement at 405 nm using a microplate
reader. The enrichment of mono- and oligonucleosomes
released into the cytoplasm was calculated using the
following formula: enrichment factor = absorbance of
sample cells/absorbance of control cells.
Xenograft mouse model and administration of diclofenac
and IR
Male BALB/c nu/nu mice were purchased from Charles
River Japan, Inc. (Yokohama, Japan). The mice were
maintained under specific pathogen-free conditions and
provided with sterile food and water, and used at 6–
8 weeks of age. All animal protocols for this experiment
were approved by the Animal Care Committee of the
Nara Medical University in accordance with the policies
established in the NIH Guide for the care and use of la-
boratory animals.
LNCaP-COX-2 cells (5 × 106 cells) in 0.05 ml of RPMI
medium, together with of 0.05 ml of Matrigel (Becton
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ously into the bilateral flanks of each mouse. When the
tumors reached 0.5 cm in diameter, the animals were
divided randomly into four groups (control, diclofenac
only, radiation only, diclofenac and radiation) (n=6 for
each group) and treatment was initiated (Day 1).
In the treated groups, diclofenac sodium 1% gel was
applied daily to the skin overlying the tumors with a cot-
ton swab. At day 3, the mice were irradiated with 3 Gy
dose using MBR-1520R X-ray unit. Only tumors treated
with irradiation were left exposed. All other regions of
the mice were shielded with lead. The tumor sizes and
volumes were measured once a week with calipers, and
the tumor volumes were calculated using the formula:
0.52 × (Length) × (Width)2.Immunohistochemical (IHC) staining
The resected tumors were fixed in 10% buffered formalin,
embedded in paraffin, and sectioned (3-μm thickness).
IHC staining for COX-2 and Ki-67 was conducted as fol-
lows: slides were deparaffinized and incubated for 5 min
with 3% H2O2 to quench the endogenous peroxidase activ-
ity. Antigen retrieval was performed for 10 min in citrate
buffer with autoclave treatment. Slides were incubated with
primary antibody at 4°C overnight. Next, the tissue sections
were incubated with mouse monoclonal anti-human
COX-2 antibody (Santa Cruz, USA) and mouse monoclo-
nal anti-human Ki-67 antibody (Dako, Glostrup, Denmark).
Sections were then developed with diaminobenzidine
(DAB), counterstained with hematoxylin, dehydrated, and
mounted.
The Ki-67 proliferative index was defined as the pro-
portion of Ki-67-positive tumor cells to the total tumor
cells.Statistics
In in vitro experiments, differences between means were
compared by the Student’s t-test. A p-value of 0.05 or
less between groups was considered significant. Data
were shown as means ± Standard deviations. In the ana-
lysis of in vivo experiments, statistical differences be-
tween the relative volumes in the treated and control
groups were analyzed using Mann–Whitney U test (stat-
istical tests were two-sided). A p-value of less than 0.05
was considered statistically significant.
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